The U.S. Food and Drug Administration (FDA) accepted for review OPKO Health’s new drug application (NDA) for a treatment for chronic kidney disease (CKD) and vitamin D insufficiency that uses Catalent’s OptiShell softgel technology as its delivery platform. OPKO Health’s product, calcifediol modified-release capsules with the proposed trade name Rayaldee, has been developed for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 CKD and vitamin D...